Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

778
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Cancer Therapies02:49

Cancer Therapies

8.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of treatment efficacy of the <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same author

Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Characterizing Heterogeneity in Behavioral Phenotypes Among Oral Nicotine Pouch Users in Saudi Arabia: A Latent Class Analysis.

Cureus·2026
Same author

Resonance Energy Transfer-Driven Photothermal Nanoagent Enables Melanoma Ablation Under Low-Power Near-Infrared Irradiation.

Advanced functional materials·2026
Same author

Dextromethorphan induces sub-chronic nephrotoxicity via modulating renin-angiotensin system, renal xenobiotic transport and drug clearance pathway.

Tissue & cell·2026
Same author

Levetiracetam elicits sub-chronic cardiotoxicity via modulating TLR4/MyD88 and NF-κB signaling axis: Mechanistic validation across molecular, functional, and structural endpoints.

Tissue & cell·2026

Related Experiment Video

Updated: Oct 27, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K

A targeted combinatorial therapy for Ewing's sarcoma.

Fahad Y Sabei1, Olena Taratula2, Hassan A Albarqi3

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, USA; Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.

Nanomedicine : Nanotechnology, Biology, and Medicine
|July 25, 2021
PubMed
Summary
This summary is machine-generated.

A new therapy combining ML111 nanoparticles and vincristine shows promise for treating relapsed Ewing sarcoma (EwS) in children and adolescents. This approach targets cancer cells effectively with minimal toxicity to healthy cells.

Keywords:
ChemotherapyCombinatorial therapyEwing's sarcomaML111Nanoparticle

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Related Experiment Videos

Last Updated: Oct 27, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.6K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Area of Science:

  • Pediatric Oncology
  • Nanomedicine
  • Drug Development

Background:

  • Ewing sarcoma (EwS) is a prevalent pediatric bone cancer with limited treatment options for relapsed cases.
  • Current chemotherapy for EwS can be ineffective in recurrent disease and leads to significant long-term side effects in survivors.

Purpose of the Study:

  • To develop a novel combinatorial therapy for EwS using a new drug candidate, ML111, and vincristine.
  • To enhance the delivery and efficacy of ML111 through polymeric nanoparticle formulation (ML111-NP).

Main Methods:

  • Formulation of hydrophobic ML111 into aqueous-soluble polymeric nanoparticles (ML111-NP).
  • In vitro evaluation of ML111-NP and ML111-NP plus vincristine combination on EwS and non-malignant cells.
  • In vivo assessment of ML111-NP accumulation and therapeutic efficacy in orthotopic EwS xenograft models.

Main Results:

  • ML111-NP demonstrated selective toxicity towards EwS cells, sparing non-malignant cells.
  • The combination of ML111-NP and vincristine showed synergistic anti-cancer effects on EwS cells but not on normal cells.
  • Intravenously administered ML111-NP effectively accumulated in EwS tumors, leading to superior therapeutic outcomes with vincristine without observable toxicity.

Conclusions:

  • ML111-NP in combination with vincristine represents a promising therapeutic strategy for relapsed Ewing sarcoma.
  • This combinatorial approach offers targeted efficacy and a favorable safety profile, addressing unmet needs in EwS treatment.